EPOR (Ab-426) Antibody

What is the specific epitope recognized by the EPOR (Ab-426) antibody?

The EPOR (Ab-426) antibody specifically recognizes a synthesized peptide derived from the internal region of human EPOR around the non-phosphorylation site of Tyrosine 426. This antibody is typically generated from rabbits immunized with this synthetic peptide . The specificity for this particular amino acid sequence makes it valuable for studying EPOR signaling mechanisms, as Tyr426 is located in a functionally significant region of the receptor's cytoplasmic domain.

How does EPOR function in normal cellular physiology?

EPOR functions as the receptor for erythropoietin (EPO), mediating erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes, triggering the JAK2/STAT5 signaling cascade . In some cell types, EPOR can also activate STAT1 and STAT3 pathways . Additionally, EPOR may activate the LYN tyrosine kinase . The isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling, providing an additional regulatory mechanism . This complex signaling network makes EPOR crucial for red blood cell development and homeostasis.

What experimental applications is the EPOR (Ab-426) antibody validated for?

Based on available research data, the EPOR (Ab-426) antibody has been validated for:

The antibody demonstrates reactivity with human samples and may cross-react with mouse and rat EPOR proteins depending on epitope conservation .

How can the EPOR (Ab-426) antibody be used to investigate EPOR phosphorylation status in diseased states?

The EPOR (Ab-426) antibody targets the non-phosphorylated form of Tyr426, making it valuable for distinguishing between activated and non-activated receptor populations. For comprehensive phosphorylation analysis:

• Use paired antibodies: Combine EPOR (Ab-426) with phospho-specific antibodies (pTyr426) to calculate activation ratios

• Employ immunoprecipitation: Pull down total EPOR and probe with phospho-specific antibodies

• Compare disease models: Recent research has identified altered EPOR phosphorylation patterns in chronic kidney disease and diabetes

Researchers investigating erythropoietin resistance should consider examining both receptor expression levels and phosphorylation status, as autoantibodies to EPOR have been found in 7.3% of patients with type 2 diabetes and chronic kidney disease .

What is the relationship between anti-EPOR autoantibodies and clinical outcomes in patients?

Research has revealed important associations between anti-EPOR autoantibodies and clinical outcomes:

In a study of patients with type 2 diabetes and chronic kidney disease, 7.3% of participants tested positive for anti-EPOR antibodies (≥2 EU) . Patients with anti-EPOR antibodies were significantly older (64.6±9.0 vs. 63.2±9.1 years, P=0.03) and more likely to have a history of cardiovascular disease (59.7% vs. 50.9%, P=0.02) compared to antibody-negative patients . This suggests potential implications for cardiovascular risk assessment in these populations. Methodologically, researchers measured these autoantibodies using indirect ELISA with a cutoff of ≥2 EU for positivity .

How do agonistic EPOR antibodies compare to native erythropoietin in receptor activation?

Agonistic EPOR antibodies represent an alternative approach to activate the erythropoietin receptor:

• Mechanistic differences: While EPO binds and induces receptor dimerization, agonistic antibodies can activate the receptor through alternative conformational changes

• Activation potency: Single agonistic antibodies typically exhibit modest bioactivity (~60% of EPO activity), but bispecific or biepitopic antibodies can achieve activity comparable to native EPO

• Signaling dynamics: A potent agonistic human antibody (ABT007) targeting EPOR has been shown to support "more sustained, and less pulsatile elevation of hematocrit" compared to standard doses of recombinant human EPO

• Structural basis: Crystal structure analysis of EPOR extracellular domain complexed with agonist antibody Fab fragments has revealed unique antibody-imposed conformational changes that differ from EPO-induced activation

What controls should be included when using EPOR (Ab-426) antibody in immunoassays?

For robust experimental design with EPOR (Ab-426) antibody:

Essential Controls:

• Positive control: Cell lysates known to express EPOR (e.g., erythroid progenitor cells)

• Negative control: Cell lines with confirmed absence of EPOR expression

• Isotype control: Rabbit IgG at equivalent concentration to assess non-specific binding

• Blocking peptide: Pre-incubation with the immunizing peptide should abolish specific signal

• Comparison with multiple anti-EPOR antibodies: Use antibodies targeting different epitopes to confirm results

When measuring anti-EPOR autoantibodies in patient samples, include control serum as a reference standard and construct a Levely-Jennings chart to monitor assay performance across experiments .

How can I optimize EPOR (Ab-426) antibody for flow cytometry applications?

For optimal flow cytometry results with EPOR (Ab-426) antibody:

• Titration experiment: Determine optimal antibody concentration (typically starting at 1.2 μg/10^6 cells based on similar antibodies)

• Sample preparation:

  • For cell surface EPOR: Use non-permeabilizing conditions

  • For total EPOR: Include permeabilization step

• Signal amplification strategies:

  • Consider using fluorophore-conjugated secondary antibodies

  • For low expression levels, biotin-streptavidin systems may enhance detection

• Analysis considerations:

  • Include fluorescence minus one (FMO) controls

  • Set gates based on negative populations

  • Consider compensation if using multiple markers

What methodology should be used to detect anti-EPOR autoantibodies in clinical samples?

Based on published research, the following methodology is recommended for detecting anti-EPOR autoantibodies:

• Use indirect enzyme-linked immunosorbent assay (ELISA) with:

  • Recombinant EPOR as coating antigen

  • Serum samples diluted appropriately (typically 1000-fold)

  • Detection using enzyme-conjugated secondary antibodies

  • Tetramethyl benzidine (TMB) as substrate

• Quantification approach:

  • Determine enzyme-linked immunosorbent assay unit (EU) using a 3-point linear approximation of control serum (set as 10 EU at a 1000-fold dilution)

  • Establish ≥2 EU as cutoff for positivity

  • Handle measurements ≤0 EU as 0.00001 EU for statistical analysis

• Quality control measures:

  • Monitor optical densities of control serum using Levely-Jennings charts

  • Include replicate measurements

  • Consider follow-up confirmation with alternative methods for positive samples

How do I distinguish between specific and non-specific binding with EPOR (Ab-426) antibody?

To ensure the specificity of your EPOR (Ab-426) antibody results:

• Validate with multiple techniques: Compare results from Western blot, immunofluorescence, and flow cytometry

• Molecular weight verification: EPOR should appear at approximately 56-59 kDa, with potential glycosylated forms at higher molecular weights

• Peptide competition assay: Pre-incubation with the immunizing peptide should substantially reduce specific signal

• Knockdown/knockout validation: Use EPOR siRNA or CRISPR-edited cells as negative controls

• Cross-validation: Compare results with antibodies targeting different EPOR epitopes, such as those recognizing AA 301-450 or AA 31-130 regions

What factors might affect the sensitivity of anti-EPOR antibody detection in complex samples?

Several factors can influence the sensitivity of EPOR antibody detection:

• Expression levels: EPOR is often expressed at low levels in non-erythroid tissues, requiring sensitive detection methods

• Isoform expression: The presence of the dominant-negative EPOR-T isoform may complicate interpretation

• Post-translational modifications:

  • Glycosylation of EPOR can alter antibody accessibility

  • Phosphorylation state may affect epitope recognition for some antibodies

• Sample preparation issues:

  • Inadequate protein denaturation for Western blotting

  • Improper fixation for immunohistochemistry

  • Protein degradation during sample handling

• Buffer conditions: Optimize pH, salt concentration, and detergent types based on experimental context

How can engineered B cells expressing anti-EPOR antibodies be used in research applications?

Recent advances in B cell engineering provide new research applications for anti-EPOR antibodies:

• Engineered B cells can be developed to express anti-EPOR antibodies using CRISPR/Cas9-mediated integration of emAb (engineered monoclonal antibody) cassettes

• The strategy involves:

  • Designing emAb cassettes containing heavy and light chains linked by glycine-serine linkers

  • Electroporation of B cells with gRNA/Cas9 targeting the immunoglobulin locus

  • Introduction of the emAb cassette via AAV-mediated homologous recombination

  • Selection and expansion of engineered B cells

• Applications include:

  • Long-term in vivo expression of anti-EPOR antibodies

  • Studying EPOR function in animal models

  • Developing therapeutic strategies for EPOR-related disorders

• Considerations:

  • Engineered B cells showed variable persistence in wild-type recipients

  • Potential off-target effects from Cas9 require careful validation

  • The approach allows both membrane-bound and secreted antibody expression

How might bispecific antibodies enhance EPOR research and potential therapeutic applications?

Bispecific antibodies represent an emerging frontier in EPOR research:

• Enhanced signaling potency: Bispecific antibodies targeting non-overlapping epitopes on EPOR have demonstrated superior agonist activity compared to monospecific antibodies

• Mechanistic insight: Studies have shown that while monospecific antibodies exhibit modest bioactivity, bispecific antibodies targeting both EPO-competitive and non-competitive epitopes can achieve activity comparable to native EPO

• Research applications:

  • Investigating receptor clustering mechanisms

  • Studying differential signaling pathway activation

  • Exploring selective tissue targeting

• Methodological approaches:

  • "Intracellular combinatorial libraries" have been used to identify synergistic antibody pairs

  • Activity-based screening systems have proven successful for identifying potent bispecific agonists

What are the implications of anti-EPOR autoantibodies for clinical research on anemia in kidney disease?

The discovery of anti-EPOR autoantibodies raises important research questions:

• Clinical correlations: While anti-EPOR antibodies were associated with increased age and cardiovascular disease history, no significant association with anemia prevalence or hemoglobin levels was observed in initial studies

• Research priorities:

  • Investigating the functional effects of these autoantibodies on EPOR signaling

  • Determining whether autoantibodies contribute to erythropoietin resistance

  • Exploring potential therapeutic interventions targeting autoantibody production or binding

• Methodological considerations:

  • Longitudinal studies are needed to assess whether antibody status changes over time

  • Combined analysis of receptor expression, phosphorylation status, and autoantibody levels

  • Integration with other known mechanisms of anemia in chronic kidney disease

• Clinical implications:

  • Potential for autoantibody testing as a biomarker for disease stratification

  • Personalized approaches to anemia management in antibody-positive patients

How do different anti-EPOR antibodies compare in research applications?

The following table summarizes key characteristics of various anti-EPOR antibodies for research comparison:

This comparison highlights the importance of selecting the appropriate antibody based on specific research questions and experimental conditions .

What advantages do agonistic anti-EPOR antibodies offer over recombinant erythropoietin?

Agonistic anti-EPOR antibodies present several potential advantages over recombinant erythropoietin:

• Pharmacokinetic benefits:

  • Longer half-life supporting less frequent dosing

  • More sustained and less pulsatile elevation of hematocrit

• Safety considerations:

  • Reduced risk of pure red cell aplasia compared to EPO products

  • Potentially different immunogenicity profile

• Mechanistic advantages:

  • Ability to induce novel conformational changes in the receptor

  • Potential for selective activation of specific downstream pathways

• Research applications:

  • Tools for dissecting receptor activation mechanisms

  • Investigation of structure-function relationships

  • Development of next-generation erythropoiesis-stimulating agents

Current research demonstrates that agonistic antibodies like ABT007 can support potent EPOR activation through unique antibody-imposed conformational changes identified through crystallographic studies .